Leukemia, Myelodysplasia, Transplantation
Conference Coverage
MRD status at transplant predicts outcomes in ALL patients
HOUSTON – Acute lymphoblastic leukemia patients with measurable residual disease (MRD) negativity prior to...
Conference Coverage
Secondary AML in first remission predicts outcomes
HOUSTON – Secondary AML predicts outcomes after SCT in first complete remission, whereas factors such as age, cytogenetics, and performance status...
Conference Coverage
Haplo-HSCT bests chemotherapy for MRD-positive adult ALL
HOUSTON – Haplo-HSCT outperforms chemotherapy for the treatment of adults with ALL in first complete response, particularly MRD-positive patients...
Conference Coverage
Anti-CD45 conditioning looks safe, feasible in relapsed AML
HOUSTON – Iomab-B use has resulted in successful engraftment for all patients who have received it and gone on to transplant, despite active...
From the Journals
HDACi, HMA combo improves survival for older AML patients
Patients older than 65 years who were ineligible for induction chemotherapy benefited from the addition of pracinostat to the standard of care...
From the Journals
Guadecitabine may be option for certain MDS/AML patients
Patients with few or no somatic mutations were more likely to respond to guadecitabine in the phase 2 trial.
From the Journals
Understanding AD as immune-driven disease has opened the door to new therapies
WASHINGTON – It was when researchers began to look at AD in the same way as psoriasis that they realized the two were “polar” immune diseases.
Conference Coverage
Post-HCT azithromycin doesn’t increase relapse risk, study suggests
HOUSTON – A prior study indicated that pretransplant azithromycin increases the risk of relapse.
From the Journals
CLL, GVHD may raise risk for skin cancer after allo-HCT
The retrospective analysis identifies previously unknown risk factor for skin cancer associated with allogeneic hematopoietic cell transplantation...
Conference Coverage
Midostaurin maintenance may reduce relapse risk in FLT3-ITD+ AML
HOUSTON – The effect was most pronounced in those with high pFLT3 inhibition on plasma inhibitor activity assay.